* 1. What is your name? What is your position?

* 2. What is the department/industry you are working for?

* 3. Are you working on Rheumatoid Arthritis or with Rheumatoid Arthritis patients?

* 4. Which therapy/combined therapies are you using / prescribing? (multiple choices possible)

  Only Infliximab (Remicade®) Adalimumab (Humira®) Golimumab (Simoni®) Etanercept (Enbrel®) Certolizumab (Cimzia®) Other

* 5. Which factors do you use to diagnose rheumatoid arthritis and / or follow the disease state?

  Always Sometimes Never
Rheumatoid factors
Anti-CCP2 Antibody test
Antinuclear antibody (ANA) test
Anti-keratin antibody (AKA) test
Vectra DA
LISA Tracker

* 6. To which purpose are you using it?

* 7. What are your criteria for choosing this /those test(s)?

* 8. If an easy, reliable monitoring test based on the dosage of soluble VE-cadherin in serum would be available to predict the responsiveness to biotherapies and / or the disease state in Rheumatoid Arthritis patients, would you consider using it?

* 9. If this test would be also an indicator of atherosclerosis in Rheumatoid Arthritis patients, how would you consider this test?

* 10. What is the main criteria you will look for using this new test?